Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 26 Results

Intervention Indication Therapeutic Area Year Actions
Pembrolizumab with chemotherapy for treating advanced or recurrent endometrial cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Pembrolizumab with Lenvatinib and chemotherapy for previously untreated advanced or metastatic gastroesophageal adenocarcinoma Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Gastroesophageal adenocarcinoma Gastrointestinal Cancer 2023 View  |  Download
Pembrolizumab with radiotherapy and chemotherapy for treating unresectable oesophageal cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) , Radiotherapy Oesophageal cancer Head and Neck Cancer 2023 View  |  Download
Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line Chemotherapy , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma Chemotherapy , Tislelizumab (BGB-A317; BGBA-317) Gastric cancer , Gastro-oesophageal junction adenocarcinoma Gastrointestinal Cancer 2022 View  |  Download
Toripalimab with chemotherapy for previously untreated recurrent or metastatic nasopharyngeal carcinoma Chemotherapy , Toripalimab Nasopharyngeal carcinoma Head and Neck Cancer 2023 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications